SciClone Financial Statements From 2010 to 2024
SciClone Pharmaceuticals financial statements provide useful quarterly and yearly information to potential SciClone Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on SciClone Pharmaceuticals financial statements helps investors assess SciClone Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting SciClone Pharmaceuticals' valuation are summarized below:SciClone Pharmaceuticals does not presently have any fundamental trend indicators for analysis.
This module can also supplement various SciClone Pharmaceuticals Technical models . Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Check SciClone Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SciClone main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . SciClone financial statements analysis is a perfect complement when working with SciClone Pharmaceuticals Valuation or Volatility modules.
SciClone |
SciClone Pharmaceuticals Company Return On Equity Analysis
SciClone Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SciClone Pharmaceuticals Return On Equity | 0.19 |
Most of SciClone Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SciClone Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, SciClone Pharmaceuticals has a Return On Equity of 0.19. This is 100.79% lower than that of the sector and 98.9% lower than that of the Return On Equity industry. The return on equity for all United States stocks is 161.29% lower than that of the firm.
SciClone Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SciClone Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare SciClone Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SciClone Pharmaceuticals competition to find correlations between indicators driving SciClone Pharmaceuticals's intrinsic value. More Info.SciClone Pharmaceuticals is rated fourth in return on equity category among related companies. It is rated second in return on asset category among related companies reporting about 0.84 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SciClone Pharmaceuticals is roughly 1.19 . Comparative valuation analysis is a catch-all model that can be used if you cannot value SciClone Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for SciClone Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SciClone Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |